Results 11 to 20 of about 35,596 (239)

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]

Clin Transl Sci
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Kim JD, Metzger IF, Lu JBL, Skaar TC, Desta Z.   +4 more
europepmc   +2 more sources

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer. [PDF]

Clin Pharmacol Ther
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Piscitelli J, Reddy MB, Wollenberg L, Del Frari L, Gong J, Matschke K, Williams JH.   +6 more
europepmc   +2 more sources

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]

, 2016
Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven, Berm, Elizabeth JJ, Boersma, Cornelis, de Looff, Margot, Postma, Maarten J, van Boven, Job FM, Vegter, Stefan, Wilffert, Bob   +7 more
core   +13 more sources

Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of the CYP2C9*2/*3 polymorphisms. [PDF]

, 2006
Background: Pharmacogenetic testing for drugmetabolizing enzymes is not yet widely used in clinical practice. Methods: In an attempt to facilitate the application of this procedure, we have compared two real-time PCRbased methods, the TaqMan_ and the ...
C. ESPOSITO, M. TORIELLO, MAZZACCARA, CRISTINA, P. MECCARIELLO, R. DI FIORE, SACCHETTI, LUCIA   +5 more
core   +1 more source

Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. [PDF]

Clin Transl Sci
ABSTRACT Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype‐specific adverse events and pharmacokinetic profiles of cannabidiol, 7‐OH cannabidiol (an active metabolite), and 7‐COOH ...
Etkins J, So GC, Lu JBL, Koyama S, Gisch DL, Melo Ferreira R, Cheng YH, McClara K, Jun J, Miller M, Desta Z, Eadon MT.   +11 more
europepmc   +2 more sources

Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency [PDF]

, 2010
Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency(ORD) present with disordered sex development and glucocorticoid deficiency.
Arlt, Bebia, Chang, de Morais, Dominique Maiter, Dorota Tomalik-Scharte, Fl  ck, Fuhr, Gomes, Hannah E Ivison, Henderson, Jetter, Julia Kirchheiner, Kelley, Kirchheiner, Kranendonk, Nebert, Nicolo, Parkinson, Porter, Ribes, Sachse, Tantcheva-Po  r, Tomalik-Scharte, Uwe Fuhr, Wiebke Arlt   +25 more
core   +2 more sources

Pharmacogenetics of analgesic drugs [PDF]

, 2013
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R, Cregg, R, Gubbay, A, Russo, G, Sato, H   +4 more
core   +1 more source

Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution Genome evolution and evolutionary systems biology [PDF]

, 2014
© 2014 Janha et al.; licensee BioMed Central Ltd.Background: Cytochrome P450 CYP2C19 metabolizes a wide range of pharmacologically active substances and a relatively small number of naturally occurring environmental toxins.
Janha, RE, Linton, KJ, Shaheen, SO, Sisay-Joof, F, Walton, RT, Worwui, A   +5 more
core   +3 more sources

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Agúndez, José Augusto, García-Martín, Elena, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge   +18 more
core   +4 more sources